Table 1.

Baseline characteristics

CharacteristicsFull analysis set
All patients of the full analysis set, N 40 
Sex, N (%) 40 
Female, n (%) 13 (32.5) 
Male, n (%) 27 (67.5) 
Age, y 40 
Median (range) 64 (40-82) 
Time since first diagnosis, mo 40 
Median (range) 103.5 (42.2-240.2) 
Binet stage, N (%) 40 
A, n (%) 11 (27.5) 
B, n (%) 19 (47.5) 
C, n (%) 10 (25.0) 
Total CIRS score 40 
Median (range) 3 (0-12) 
Creatinine clearance (mL/min) 40 
Median (range) 82.1 (35.6-153.1) 
del(17p), N (%) 40 
Yes, n (%) 5 (12.5) 
del(11q), N (%) 40 
Yes, n (%) 15 (37.5) 
Trisomy 12, N (%) 40 
Yes, n (%) 3 (7.5) 
del(13q), N (%) 40 
Yes, n (%) 23 (57.5) 
Type according to hierarchical model, N (%) 40 
del(17p), n (%) 5 (12.5) 
del(11q), n (%) 15 (37.5) 
Trisomy 12, n (%) 1 (2.5) 
Not del(17p)/del(11q)/trisomy 12/del(13q), n (%) 9 (22.5) 
del(13q) alone, n (%) 10 (25.0) 
IGHV mutational status, N (%) 40 
Unmutated, n (%) 31 (77.5) 
Mutated, n (%) 9 (22.5) 
TP53 mutational status, N (%) 40 
Unmutated, n (%) 26 (65.0) 
Mutated, n (%) 14 (35.0) 
TP53 status, N (%) 40 
None, n (%) 25 (62.5) 
Deleted and/or mutated, n (%) 15 (37.5) 
NOTCH1 mutational status, N (%) 40 
Unmutated, n (%) 30 (75.0) 
Mutated, n (%) 10 (25.0) 
SF3B1 mutational status, N (%) 40 
Unmutated, n (%) 27 (67.5) 
Mutated, n (%) 13 (32.5) 
Serum β2-microglobulin (mg/dL) 39 
Median (range) 4.5 (2.1-17.2) 
Complex karyotype, N (%) 38 
Noncomplex karyotype (<3 aberrations), n (%) 19 (50.0) 
Complex karyotype (≥3 aberrations), n (%) 19 (50.0) 
CLL-IPI risk group, N (%) 39 
Low, n (%) 2 (5.1) 
Intermediate, n (%) 6 (15.4) 
High, n (%) 18 (46.2) 
Very high, n (%) 13 (33.3) 
Previous lines of treatment 40 
Median (range) 1 (1-5) 
Previous treatment with venetoclax, N (%) 40 
Yes, n (%) 7 (17.5) 
Previous treatment with a BTKi, N (%) 40 
Yes, n (%) 18 (45.0) 
Previous treatment with a BTKi and venetoclax, N (%) 40 
Yes, n (%) 5 (12.5) 
Previous treatment with a BTKi and/or venetoclax, N (%) 40 
Yes, n (%) 20 (50.0) 
CharacteristicsFull analysis set
All patients of the full analysis set, N 40 
Sex, N (%) 40 
Female, n (%) 13 (32.5) 
Male, n (%) 27 (67.5) 
Age, y 40 
Median (range) 64 (40-82) 
Time since first diagnosis, mo 40 
Median (range) 103.5 (42.2-240.2) 
Binet stage, N (%) 40 
A, n (%) 11 (27.5) 
B, n (%) 19 (47.5) 
C, n (%) 10 (25.0) 
Total CIRS score 40 
Median (range) 3 (0-12) 
Creatinine clearance (mL/min) 40 
Median (range) 82.1 (35.6-153.1) 
del(17p), N (%) 40 
Yes, n (%) 5 (12.5) 
del(11q), N (%) 40 
Yes, n (%) 15 (37.5) 
Trisomy 12, N (%) 40 
Yes, n (%) 3 (7.5) 
del(13q), N (%) 40 
Yes, n (%) 23 (57.5) 
Type according to hierarchical model, N (%) 40 
del(17p), n (%) 5 (12.5) 
del(11q), n (%) 15 (37.5) 
Trisomy 12, n (%) 1 (2.5) 
Not del(17p)/del(11q)/trisomy 12/del(13q), n (%) 9 (22.5) 
del(13q) alone, n (%) 10 (25.0) 
IGHV mutational status, N (%) 40 
Unmutated, n (%) 31 (77.5) 
Mutated, n (%) 9 (22.5) 
TP53 mutational status, N (%) 40 
Unmutated, n (%) 26 (65.0) 
Mutated, n (%) 14 (35.0) 
TP53 status, N (%) 40 
None, n (%) 25 (62.5) 
Deleted and/or mutated, n (%) 15 (37.5) 
NOTCH1 mutational status, N (%) 40 
Unmutated, n (%) 30 (75.0) 
Mutated, n (%) 10 (25.0) 
SF3B1 mutational status, N (%) 40 
Unmutated, n (%) 27 (67.5) 
Mutated, n (%) 13 (32.5) 
Serum β2-microglobulin (mg/dL) 39 
Median (range) 4.5 (2.1-17.2) 
Complex karyotype, N (%) 38 
Noncomplex karyotype (<3 aberrations), n (%) 19 (50.0) 
Complex karyotype (≥3 aberrations), n (%) 19 (50.0) 
CLL-IPI risk group, N (%) 39 
Low, n (%) 2 (5.1) 
Intermediate, n (%) 6 (15.4) 
High, n (%) 18 (46.2) 
Very high, n (%) 13 (33.3) 
Previous lines of treatment 40 
Median (range) 1 (1-5) 
Previous treatment with venetoclax, N (%) 40 
Yes, n (%) 7 (17.5) 
Previous treatment with a BTKi, N (%) 40 
Yes, n (%) 18 (45.0) 
Previous treatment with a BTKi and venetoclax, N (%) 40 
Yes, n (%) 5 (12.5) 
Previous treatment with a BTKi and/or venetoclax, N (%) 40 
Yes, n (%) 20 (50.0) 

CIRS, cumulative illness rating scale; IGHV, immunoglobulin heavy chain variable region gene; IPI, International Prognostic Index.

Close Modal

or Create an Account

Close Modal
Close Modal